tbuckley/cabot-search huggingface dataset:
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
Authors: Paul C Cremer, Antonio Abbate, Kristin Hudock, Carla McWilliams, Jinesh Mehta, Steven Y Chang, Calvin C Sheng, Benjamin Van Tassell, Aldo Bonaventura, Alessandra Vecchié, Brenna Carey, Qiuqing Wang, Katherine E Wolski, Prabalini Rajendram, Abhijit Duggal, Tisha S Wang, John F Paolini, Bruce C Trapnell, Deborah Gladish, Karen Myers, Yuki Kuramochi, Christina Sewell, Craig Balog, Denise Kosty Sweeny, Jill Kandrac, Stephanie Spencer, Alice Goyanes, Debasis Sahoo, Siddharth Dugar, Robier Aguillon Prada, Dave Nichols, Jeannie Celiberti, Annie Partisano, Fang Fang, Jennifer Coehlo, Randy Perrin, Brian Mandell, Steven Gordon, Herbert Wiedemann, James Young, Joan Greer, Ai-Chen Ho, Any Ladd, Virginia Mihalick, Alison Montpetit, Joyce O'Brine, Catherine Owen, Mary Pal, Anna Priday, Yub Raj Sedhai, George Wohlford, Nicole Hummel, Leslie Korbee
Journal: The Lancet Rheumatology (2021)

In patients with COVID-19, granulocyte-macrophage colony stimulating factor (GM-CSF) might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. We aimed to evaluate whether mavrilimumab, a monoclonal antibody to the GM-CSF receptor, would improve outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation.This investigator-initiated, multicentre, double-blind, randomised trial was done at seven hospitals in the USA. Inclusion required hospitalisation, COVID-19 pneumonia, hypoxaemia, and a C-reactive protein concentration of more than 5 mg/dL. Patients were excluded if they required mechanical ventilation. Patients were randomly assigned (1:1) centrally, with stratification by hospital site, to receive mavrilimumab 6 mg/kg as a single intravenous infusion, or placebo. Participants and all clinical and research personnel were masked to treatment assignment. The primary endpoint was the proportion of patients alive and off supplemental oxygen therapy at day 14. The primary outcome and safety were analysed in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT04399980, NCT04463004, and NCT04492514.Between May 28 and Sept 15, 2020, 40 patients were enrolled and randomly assigned to mavrilimumab (n=21) or placebo (n=19). A trial of 60 patients was planned, but given slow enrolment, the study was stopped early to inform the natural history and potential treatment effect. At day 14, 12 (57%) patients in the mavrilimumab group were alive and off supplemental oxygen therapy compared with nine (47%) patients in the placebo group (odds ratio 1·48 [95% CI 0·43-5·16]; p=0·76). There were no treatment-related deaths, and adverse events were similar between groups.There was no significant difference in the proportion of patients alive and off oxygen therapy at day 14, although benefit or harm of mavrilimumab therapy in this patient population remains possible given the wide confidence intervals, and larger trials should be completed.Kiniksa Pharmaceuticals.
The year in basic vascular biology research: from mechanoreceptors and neutrophil extracellular traps to smartphone data and omics
Authors: Paul Evans, Johann Wojta, Imo E Hoefer, Johannes Waltenberger, Tomasz Guzik, Lina Badimon, Christian Weber
Journal: Cardiovascular Research (2021)

2020 has been an extraordinary year. The emergence of COVID-19 has driven urgent research in pulmonary and cardiovascular science and other fields. It has also shaped the way that we work with many experimental laboratories shutting down for several months, while bioinformatics approaches and other large data projects have gained prominence. Despite these setbacks, vascular biology research is stronger than ever. On behalf of the European Society of Cardiology Council for Basic Cardiovascular Science (ESC CBCS), here we review some of the vascular biology research highlights for 2020. This review is not exhaustive and there are many outstanding vascular biology publications that we were unable to cite due to page limits. Notwithstanding this, we have provided a snapshot of vascular biology research excellence in 2020 and identify topics that are in the ascendency and likely to gain prominence in coming years.
Paclitaxel Induces Drug-resistance to Paclitaxel in Vascular Smooth Muscle Cells and Reduces Its Effect of Suppression of Neointimal Hyperplasia
Authors: Yang Han-Mo, Cho Hyun-Ju, Park Kyung-Woo, Cho Hyun-Jai, Kang Hyun-Jae, Koo Bon-Kwon, Sohn Dae-Won, OH Byung-Hee, Park Young-Bae, Kim Hyo-Soo
Journal: Circulation (2011)
Longitudinal Detection of DNMT3A R882H Transcripts in Patients with Acute Myeloid Leukemia
Authors: Tiziana Ottone, Valentina Alfonso, Licia Iaccarino, Syed Khizer Hasan, Melissa Mancini, Mariadomenica Divona, Serena Lavorgna, Laura Cicconi, Paola Panetta, Luca Maurillo, Maria Ilaria Del Principe, Maria irno Consalvo, Luca Franceschini, Daniela Angelini, Luca Battistini, Gisella Guerrera, Marco de Bardi, Emiliano Fabiani, Giulia Falconi, William Arcese, Sergio Amadori, Francesco Buccisano, Adriano Venditti, Maria Teresa Voso, Francesco Lo Coco
Journal: Blood (2017)
Abstract 12566: Liver Health in Adults With Fontan Circulation: A Multicenter Cross-Sectional Study
Authors: Fred Wu, Amy Harmon, Brian Kogon, Michael G Earing, Jamil A Aboulhosn, Craig S Broberg, Anitha S John, Nisha I Sainani, Andrew J Hill, Robert D Odze, Melanie E Johncilla, Chinweike Ukomadu, Kimberlee Gauvreau, Anne M Valente, Michael J Landzberg, Aarcc Investigators
Journal: Circulation (2013)

Background: Liver disease is increasingly recognized in patients with Fontan circulation and may contribute to morbidity and mortality. There has been no large-scale survey of liver health in this ...
OA09.05 Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy
Authors: K. Kerrigan, J. Chipman, Y.J. Jo, B. Haaland, E. Johnson, S. Puri, T. Varghese, W. Akerley, S. Patel
Journal: Journal of Thoracic Oncology (2021)
OA02.04 Randomized Phase Ⅱ Trial (RTOG1106) on Midtreatment PET/CT Guided Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer
Authors: F. Kong, C. Hu, M. Machtay, M. Matuszak, Y. Xiao, R. Ten Haken, V. Hirsh, D. Pryma, B.A. Siegel, D. Gelblum, J. Hayman, C. Robinson, B. Loo, G. Videtic, S.L. Faria, C. Ferguson, N. Dunlap, V. Kundapu, R. Paulus, W. Curran, J. Bradley
Journal: Journal of Thoracic Oncology (2021)
P01.09 Improved Outcomes With Ramucirumab &amp; Docetaxel in Metastatic Non-Small Cell Lung Cancer After Failure of Immunotherapy
Authors: R. Dawar, K. Gawri, E. Rodriguez, V. Thammineni, E. Saul, J.O. Oliveira Lima Filho, N. Dempsey, K. Khan, T. Torres, D. Kwon, G. Lopes
Journal: Journal of Thoracic Oncology (2021)
P01.23 Veliparib (V) in Combination with Carboplatin/Paclitaxel (C/P)-Based Chemoradiotherapy (CRT) in Patients With Stage III NSCLC
Authors: D. Kozono, T. Stinchcombe, J. Salama, J. Bogart, W. Petty, M. Guarino, L. Bazhenova, J. Larner, J. Weiss, T. Dipetrillo, S. Feigenberg, X. Chen, Z. Sun, S. Nuthalapati, L. Rosenwinkel, E. Johnson, B. Bach, Y. Luo, E. Vokes
Journal: Journal of Thoracic Oncology (2021)
Sublingual vaccination and delivery systems
Authors: A.L. Paris, E. Colomb, B. Verrier, F. Anjuère, C. Monge
Journal: Journal of Controlled Release (2021)

Most infectious agents use mucosal tissues as entry portals, thus, mucosae are frequently defined as a first line of defense against pathogens. Mucosal protection generally operates through antibody-mediated and cytotoxic T-cell responses which can be triggered by mucosal vaccines. Sublingual vaccination provides many advantages such as systemic and mucosal responses (both locally and at remote mucosal sites), besides being a needle-free administration route with high patient compliance and limited adverse effects. Buccal mucosa complexity nonetheless represents a challenge for vaccine administration, hence, many efforts were recently deployed to improve vaccine components, mucoadhesion and/or penetration. Several innovative approaches indeed confirmed that a robust and protective immunity can be achieved by sublingual vaccines. This review will then specify the most recent delivery systems and improvements developed to increase sublingual vaccines efficiency. We will focus our description on the immune mechanisms involved and the requirements for optimal sublingual immunization and mucosal protection.
Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment
Authors: Ester Pagano, Joshua E Elias, Georg Schneditz, Svetlana Saveljeva, Lorraine M Holland, Francesca Borrelli, Tom H Karlsen, Arthur Kaser, Nicole C Kaneider
Journal: Gut (2021)

Primary sclerosing cholangitis (PSC) is in 70% of cases associated with inflammatory bowel disease. The hypermorphic T108M variant of the orphan G protein-coupled receptor GPR35 increases risk for PSC and ulcerative colitis (UC), conditions strongly predisposing for inflammation-associated liver and colon cancer. Lack of GPR35 reduces tumour numbers in mouse models of spontaneous and colitis associated cancer. The tumour microenvironment substantially determines tumour growth, and tumour-associated macrophages are crucial for neovascularisation. We aim to understand the role of the GPR35 pathway in the tumour microenvironment of spontaneous and colitis-associated colon cancers.Mice lacking GPR35 on their macrophages underwent models of spontaneous colon cancer or colitis-associated cancer. The role of tumour-associated macrophages was then assessed in biochemical and functional assays.Here, we show that GPR35 on macrophages is a potent amplifier of tumour growth by stimulating neoangiogenesis and tumour tissue remodelling. Deletion of Gpr35 in macrophages profoundly reduces tumour growth in inflammation-associated and spontaneous tumour models caused by mutant tumour suppressor adenomatous polyposis coli. Neoangiogenesis and matrix metalloproteinase activity is promoted by GPR35 via Na/K-ATPase-dependent ion pumping and Src activation, and is selectively inhibited by a GPR35-specific pepducin. Supernatants from human inducible-pluripotent-stem-cell derived macrophages carrying the UC and PSC risk variant stimulate tube formation by enhancing the release of angiogenic factors.Activation of the GPR35 pathway promotes tumour growth via two separate routes, by directly augmenting proliferation in epithelial cells that express the receptor, and by coordinating macrophages' ability to create a tumour-permissive environment.
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
Authors: Candice L. Clarke, Maria Prendecki, Amrita Dhutia, Jaslyn Gan, Claire Edwards, Virginia Prout, Liz Lightstone, Eleanor Parker, Federica Marchesin, Megan Griffith, Rawya Charif, Graham Pickard, Alison Cox, Myra McClure, Richard Tedder, Paul Randell, Louise Greathead, Mary Guckian, Stephen P. McAdoo, Peter Kelleher, Michelle Willicombe
Journal: Kidney International (2021)

Patients with end stage kidney disease receiving in-center hemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. Following infection, patients receiving ICHD frequently develop circulating antibodies to SARS-CoV-2, even with asymptomatic infection. Here, we investigated the durability and functionality of the immune responses to SARS-CoV-2 infection in patients receiving ICHD. Three hundred and fifty-six such patients were longitudinally screened for SARS-CoV-2 antibodies and underwent routine PCR-testing for symptomatic and asymptomatic infection. Patients were regularly screened for nucleocapsid protein (anti-NP) and receptor binding domain (anti-RBD) antibodies, and those who became seronegative at six months were screened for SARS-CoV-2 specific T-cell responses. One hundred and twenty-nine (36.2%) patients had detectable antibody to anti-NP at time zero, of whom 127 also had detectable anti-RBD. Significantly, at six months, 71/111 (64.0%) and 99/116 (85.3%) remained anti-NP and anti-RBD seropositive, respectively. For patients who retained antibody, both anti-NP and anti-RBD levels were reduced significantly after six months. Eleven patients who were anti-NP seropositive at time zero, had no detectable antibody at six months; of whom eight were found to have SARS-CoV-2 antigen specific T cell responses. Independent of antibody status at six months, patients with baseline positive SARS-CoV-2 serology were significantly less likely to have PCR confirmed infection over the following six months. Thus, patients receiving ICHD mount durable immune responses six months post SARS-CoV-2 infection, with fewer than 3% of patients showing no evidence of humoral or cellular immunity.
Migraine: disease characterisation, biomarkers, and precision medicine
Authors: Messoud Ashina, Gisela M Terwindt, Mohammad Al-Mahdi Al-Karagholi, Irene de Boer, Mi Ji Lee, Debbie L Hay, Laura H Schulte, Nouchine Hadjikhani, Alexandra J Sinclair, Håkan Ashina, Todd J Schwedt, Peter J Goadsby
Journal: The Lancet (2021)
P19.02 Association between Number of Residual Metastases and Patterns of Progression on EGFR TKI in EGFR mutated Non-Small Cell Lung Cancer
Authors: T. Miyawaki, H. Kenmotsu, M. Yabe, H. Kodama, N. Nishioka, E. Miyawaki, N. Mamesaya, H. Kobayashi, S. Omori, K. Wakuda, A. Ono, T. Naito, H. Murakami, K. Mori, H. Harada, T. Takahashi
Journal: Journal of Thoracic Oncology (2021)
Phenotypic and genomic characterization of intratumoral heterogeneity in high-grade serous ovarian cancer.
Authors: Paula Cunnea, Ed Curry, Katherine Nixon, Ratri Wulandari, Kerstin Thol, Chun Hei Kwok, Jennifer Ploski, Iain McNeish, Elizabeth Christie, David Bowtell, Christina Fotopoulou
Journal: Clinical Cancer Research (2020)
Near-Infrared Spectroscopy Intravascular Ultrasound Imaging Evaluation in Patients With Chronic Renal Insufficiency
Authors: Kazuhiro Dan, Rebecca Torguson, Paige E. Craig, Cheng Zhang, Corey Shea, Carlo Di Mario, Hector M. Garcia-Garcia, Gary S. Mintz, Ron Waksman
Journal: JACC. Cardiovascular imaging (2021)
OA11.05 Whole Exome Sequencing Reveals the Potential Role of Hereditary Predisposition in Small Cell Lung Cancer, a Tobacco-Related Cancer
Authors: N. Takahashi, C. Tlemsani, L. Pongor, V. Rajapakse, M. Tyagi, X. Wen, G. Fasaye, K. Schmidt, C. Kim, A. Rajan, S. Swift, L. Sciuto, R. Vilimas, S. Webb, S. Nichols, W.D. Figg, Y. Pommier, K. Calzone, S. Steinberg, J. Wei, U. Guha, C. Turner, J. Khan, A. Thomas
Journal: Journal of Thoracic Oncology (2021)
Inflammatory skin diseases and the risk of chronic kidney disease: population‐based case–control and cohort analyses*
Authors: Y. Schonmann, K.E. Mansfield, A. Mulick, A. Roberts, L. Smeeth, S.M. Langan, D. Nitsch
Journal: British Journal of Dermatology (2021)

Emerging evidence suggests an association between common inflammatory skin diseases and chronic kidney disease (CKD).
LncRNA SAMMSON Mediates Adaptive Resistance to RAF Inhibition in BRAF-Mutant Melanoma Cells
Authors: Shujun Han, Yuwei Yan, Yibo Ren, Yiming Hu, Yan Wang, Lei Chen, Zhe Zhi, Yan Zheng, Yongping Shao, Jiankang Liu
Journal: Cancer Research (2021)

Abstract The long noncoding RNA (lncRNA) SAMMSON is required for human melanoma cell growth and survival. However, whether SAMMSON regulates the response of mutant BRAF melanoma cells to RAF inhibitors remains unknown. In this work, we showed that SAMMSON is rapidly induced upon inhibition of ERK signaling, and SAMMSON overexpression conferred resistance to vemurafenib-induced cytotoxicity in melanoma cells. SOX10 mediated transcriptional induction of SAMMSON by vemurafenib, and SOX10 sumoylation at K55 was essential for this function. In addition, depletion of SAMMSON activated p53 signaling, which is dependent on the SAMMSON-interacting protein CARF. Depletion of SAMMSON sensitized mutant BRAF melanoma cells to RAF inhibitors in vitro and in vivo, while CARF knockdown reversed the enhanced sensitivity. In summary, these findings suggest that SAMMSON may function as a new mediator of adaptive resistance to RAF inhibitors in melanoma by modulating CARF-p53 signaling. Significance: This study highlights the role of a SAMMSON/CARF/p53 signaling axis in modulating the adaptive resistance of mutant BRAF melanoma to RAF inhibitors.
P48.14 RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting
Authors: L. Paz-Ares, D.R. Spigel, Y. Chen, M. Jove, O. Juan-Vidal, P. Rich, T. Hayes, V. Gutiérrez Calderón, R.B. Caro, A. Navarro Mendivil, A. Dowlati, B. Zhang, Y. Moore, T. Wang, J. Kokhreidze, S. Ponce, P. Bunn
Journal: Journal of Thoracic Oncology (2021)
P78.14 The Efficacy and Safety of ICIs in Treating Postoperative Recurrence of NSCLC: Results of Two Hospitals in Japan
Authors: Y. Yagi, K. Kojima, T. Sakurai, T. Sakamoto, K. In, A. Tamiya, S. Atagi, T. Momozane, Y. Kimura, H. Kishima, K. Kodama
Journal: Journal of Thoracic Oncology (2021)
Individualized Treatment Summaries and Survivorship Care Plans (SCPs) for Hematopoietic Cell Transplant (HCT) Survivors Reduces Cancer Treatment Distress in a Randomized, Multicenter Study
Authors: Navneet S. Majhail, Elizabeth Anne Murphy, Purushottam Laud, Jaime Preussler, Ellen Denzen, Alexia Adams, RaeAnne Besser, Linda J. Burns, Jan Cerny, Rebecca Drexler, Theresa Hahn, Lensa Idossa, Balkrishna Jahagirdar, Naynesh Kamani, Alison W. Loren, Deborah Mattila, Joseph P. McGuirk, Heather Moore, Jana Reynolds, Wael Saber, Lizette Salazar, Barry Schatz, Patrick J. Stiff, John Wingard, Karen L. Syrjala, K. Scott Baker
Journal: Blood (2017)
P05.04 Association of Lymphopenia and Disease Progression in Unresectable NSCLC Treated with Definitive Chemoradiation and Immunotherapy
Authors: C. Friedes, T. Chakrabarti, S. Olson, L. Prichett, J. Brahmer, P. Forde, R. Voong, K. Marrone, V. Lam, C. Hann, S. Broderick, R. Battafarano, J. Ha, E. Bush, S. Yang, M. Brock, R. Hales, J. Feliciano
Journal: Journal of Thoracic Oncology (2021)
Nanotechnology‐Based Strategies to Evaluate and Counteract Cancer Metastasis and Neoangiogenesis
Authors: Özlem Şen, Melis Emanet, Gianni Ciofani
Journal: Advanced Healthcare Materials (2021)

Abstract Cancer metastasis is the major cause of cancer‐related morbidity and mortality. It represents one of the greatest challenges in cancer therapy, both because of the ability of metastatic cells to spread into different organs, and because of the consequent heterogeneity that characterizes primary and metastatic tumors. Nanomaterials can potentially be used as targeting or detection agents owing to unique chemical and physical features that allow tailored and tunable theranostic functions. This review highlights nanomaterial‐based approaches in the detection and treatment of cancer metastasis, with a special focus on the evaluation of nanostructure effects on cell migration, invasion, and angiogenesis in the tumor microenvironment.
P47.03 Understanding Lung Neuroendocrine Tumor Progression Combining Organoid Models and Multi-Omic Analyses
Authors: N. Alcala, T. Dayton, L. Mangiante, L. Den Hartigh, S. Levy, J. Van Den Berg, L. Moonen, J. Derks, W. Buikhuisen, E.J. Speel, G. Valk, M. Tesselaar, M. Vriens, H. Clevers, M. Foll, L. Fernandez-Cuesta
Journal: Journal of Thoracic Oncology (2021)
Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor
Authors: Shinsuke Kataoka, Nozomu Kawashima, Yusuke Okuno, Hideki Muramatsu, Shunsuke Miwata, Kotaro Narita, Motoharu Hamada, Norihiro Murakami, Rieko Taniguchi, Daisuke Ichikawa, Hironobu Kitazawa, Kyogo Suzuki, Eri Nishikawa, Atsushi Narita, Nobuhiro Nishio, Hidenori Yamamoto, Yoshie Fukasawa, Taichi Kato, Hiroyuki Yamamoto, Jun Natsume, Seiji Kojima, Ichizo Nishino, Takeshi Taketani, Hidenori Ohnishi, Yoshiyuki Takahashi
Journal: Journal of Allergy and Clinical Immunology (2021)
Abstract 15680: Validation of Remote Measurement of the Qtc Intervals Using an Apple Watch
Authors: Carmen Spaccarotella, serena migliarino, annalisa mongiardo, Jolanda Sabatino, Giuseppe Santarpia, Antonio Curcio, Salvatore De Rosa, Ciro Indolfi
Journal: Circulation (2020)

Introduction: In many circumstances, especially in the Covid-19 period, it could be necessary to measure the QT interval repeatedly even daily. Hypothesis: The aim of the study was to evaluate the feasibility of remote measuring LI-LII and V2 leads with using a commercially available Apple Watch Series 4. Methods: The accuracy of the QTc calculation with the smartwatch compared to the standard ECG was tested using di!erent formulae. One hundred patients admitted to our CCU were studied. LI-LII and V2 tracings were obtained immediately after the recording of the standard 12-lead ECG. The LI was recorded with the smartwatch on the left wrist and the right index finger on the crown; LII was obtained with the watch on the left lower abdomen and the right index finger on the crown; V2 lead was recorded with a smartwatch in the fourth intercostal space left parasternal with the right index finger on the crown. All recorded 30” ECGs were digitally stored using the health application of an iPhone Series 10 in the pdf format. The advantage of saving the ECG in pdf format is that it can be sent also via e-mail. Results: There was an agreement between the QTLI, QT-LII, QT-V2 and QT mean intervals of smartphone electrocardiography tracings and standard electrocardiography using Spearman’s correlation coefficient of 0.881; 0.885; 0.801; 0.911 respectively [p&lt;0.001]. The reliability of the mean QTc measurements was tested with Bland-Altman analysis using Bazett’s, Friedericia’s, and Framingham’s formulas between standard ECG and smartwatch(Figure). Conclusions: These data demonstrated the feasibility to measure the QTc in LI, LII and V2 leads with a smartwatch with results comparable to that performed with the standard ECG. These data could have an important clinical impact both for the widespread di!usion of smartwatches and for the monitoring of drug-induced QT interval prolongation, especially in the Covid-19 era.
SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
Authors: Alona Kuzmina, Yara Khalaila, Olga Voloshin, Ayelet Keren-Naus, Liora Boehm-Cohen, Yael Raviv, Yonat Shemer-Avni, Elli Rosenberg, Ran Taube
Journal: Cell Host & Microbe (2021)
P83.03 Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation
Authors: G. Gao, Y. Wang, S. Ren, Z. Liu, G. Chen, K. Gu, A. Zang, J. Zhao, R. Guo, J. He, X. Lin, Y. Pan, Z. Ma, Z. Wang, M. Fan, Y. Liu, S. Cang, X. Yang, Q. Wang, C. Zhou
Journal: Journal of Thoracic Oncology (2021)
Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis
Authors: Jürgen Behr, David Pittrow, Jens Klotsche
Journal: European Respiratory Journal (2021)

We thank S. Suissa and D. Assayag, as well as J. Borchardt, for their interest in our study and for giving us the opportunity to respond to their comments regarding the potential impact of immortal time bias and lead time bias on the observed difference between idiopathic pulmonary fibrosis (IPF) patients treated with or without antifibrotic drugs under real-life conditions. As a key finding of the INSIGHTS-IPF Registry follow-up analysis, we had reported that survival was significantly higher in IPF patients receiving antifibrotic therapy when compared with propensity-matched IPF patients not receiving such drugs [1]. Survival differences favouring antifibrotic therapy from INSIGHTS-IPF registry data are not compromised by immortal and lead time biases <https://bit.ly/3tDpk1S>
FP01.04 BTCRC LUN19-396: Adjuvant Chemotherapy Plus Atezolizumab in Stage IB-IIIA Resected NSCLC and Clearance of ctDNA
Authors: M. Yan, G. Durm, S. Jalal, L. Einhorn, K. Kesler, K. Rieger, T. Birdas, D. Ceppa, N. Hanna
Journal: Journal of Thoracic Oncology (2021)